OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Ignacio Duran, MD, PhD

home / authors / ignacio-duran-md-phd

Articles

Advertisement

Expert on mUC

Metastatic Urothelial Carcinoma: Unmet Needs and Future Directions

February 16th 2022

Expert reflection on the current unmet needs in metastatic urothelial carcinoma and hope for future improvements in the treatment armamentarium.

Read More


Expert on mUC

Treatment Options After Frontline Maintenance Therapy in mUC

February 16th 2022

Following frontline maintenance therapy in metastatic urothelial carcinoma, Ignacio Duran, MD, PhD, considers optimal second-line treatment options.

Read More


Expert on mUC

Metastatic Urothelial Carcinoma: Optimizing Use of Frontline Maintenance Therapy

February 9th 2022

Shared insight on the use of maintenance therapy in metastatic urothelial carcinoma with regard to PD-L1 testing and patient education.

Read More


Expert on mUC

Interpreting JAVELIN Bladder 100: Avelumab in Metastatic Urothelial Carcinoma

February 9th 2022

Ignacio Duran, MD, PhD, reflects on the JAVELIN Bladder 100 trial, which analyzed avelumab as frontline maintenance therapy in metastatic urothelial carcinoma.

Read More


Expert on mUC

Immunotherapy’s Roles in Treating Metastatic Urothelial Carcinoma

February 2nd 2022

Considerations for the role of immunotherapy in metastatic urothelial carcinoma as maintenance or switch therapy.

Read More


Expert on mUC

A Global View on Metastatic Urothelial Carcinoma

February 2nd 2022

Expert perspective on the current treatment paradigm of metastatic urothelial carcinoma across different regions of the world.

Read More

Latest Conference Coverage

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact